UK markets open in 13 minutes
NIKKEI 225
39,583.08 +241.54 (+0.61%) HANG SENG
17,733.97 +17.50 (+0.10%) CRUDE OIL
82.29 +0.55 (+0.67%) GOLD FUTURES
2,336.90 +0.30 (+0.01%) DOW
39,164.06 +36.26 (+0.09%) Bitcoin GBP
48,683.53 +679.49 (+1.42%)
Pharma Mar, S.A. (PMRA.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 08:05AM CEST. Market open.
| Previous close | 33.44 |
| Open | 32.50 |
| Bid | 32.52 x N/A |
| Ask | 32.92 x N/A |
| Day's range | 32.50 - 32.50 |
| 52-week range | 26.06 - 43.90 |
| Volume | |
| Avg. volume | 5 |
| Market cap | 567.645M |
| Beta (5Y monthly) | -0.01 |
| PE ratio (TTM) | 295.45 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.65 (1.94%) |
| Ex-dividend date | 12 Jun 2024 |
| 1y target est | N/A |
- PR Newswire
PharmaMar presents encouraging results at ASCO for Small Cell Lung Cancer
PharmaMar (MSE: PHM), world leader in the discovery, development and commercialization of marine-derived cancer treatments, presented data from a Phase II trial evaluating PharmaMar's lurbinectedin in combination with irinotecan in patients with relapsed Small Cell Lung Cancer (SCLC) after prior platinum-based treatment at the American Society of Clinical Oncology (ASCO) meeting, which took place from 31st May to 4th June in Chicago, United States.
© 2024 Yahoo. All rights reserved.